News Irish study promises to revolutionise childhood cancer care A five-year genomics study that aims to transform the care of children with cancer and improve treatment success has launched in Ireland.
R&D Harnessing genetics to propel cancer research and clinical s... When navigating the landscape of pharmaceutical development, clinical trials represent both a crucial checkpoint and a formidable barrier.
R&D Ageing Europe - It’s time we prioritised neurological condit... Europeans are living longer than ever before – tangible proof of the phenomenal advancements in science and healthcare.1,2 However, it comes with a paradoxical rise in nervous sy
R&D Applying genetics to chemistry to find new small molecules For all the advances that have been made in it, drug discovery is still a hit or miss process, as much an art as a science.
R&D Data-driven disease research harnessing the genome Ben Hargreaves speaks to the UK Biobank to learn more about their work building a dataset of 500,000 individuals.
News 23andMe doses first patient in ph2a anti-tumour monotherapy Additionally, the company will be making investor presentations today and next week.
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.